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Dear Professor Seymour,  
We report here a multi-center, single-arm, phase II, prospective clinical trial assessing the 
efficacy and tolerability of fludarabine and cyclophosphamide (FluCy) followed by 
consolidation with thalidomide in previously untreated Angioimmunoblastic T-cell 
lymphoma (AITL). 
AITL is a rare disease accounting for 1-2% of non-Hodgkin lymphomas (NHL) in Europe and 
North America [1].  The median age at presentation is 62-70 years and 80-90% of patients 
have advanced stage disease [2-6]. It typically follows an aggressive course with poor 
prognosis; although complete remission (CR) is achieved in 44-61% of patients, relapses are 
frequent and the median overall survival (OS) is approximately 3 years with 5-year survival 
of 32% [2, 3, 6]. Due to its low incidence, there have been few prospective clinical trials in 
AITL and most data informing treatment strategies are derived from retrospective and 
registry studies. Most patients are treated with combination chemotherapy containing 
anthracyclines but in a large retrospective study, no survival advantage was identified for 
these patients compared to those treated with non-anthracycline-containing regimens [2].  
Evidence from case reports and small series indicates that purine analogues are efficacious 
in AITL [7,8]. The combination of fludarabine and cyclophosphamide (FluCy) is active in 
other lymphoproliferative disorders but has not been assessed in AITL [9]. The high relapse 
rate suggests that consolidation or maintenance strategies may be beneficial in the 
management of AITL; whilst autologous stem cell transplantation (ASCT) is sometimes used 
in first remission, this is not an option for all patients. Preliminary evidence from case 
reports supports the use of thalidomide as maintenance therapy but there have been no 
trials assessing it [10-12].  
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This trial was designed as a sequential 2-stage trial to evaluate the response rate of 
previously untreated AITL to FluCy chemotherapy and the incremental response rate to 
thalidomide maintenance. A Bayesian 2-stage design was used, assuming that a CR rate of 
<40% would not be of further interest, while a CR rate of ≥60% with FluCy would be of 
interest to test in further trials. Setting a threshold probability of 0.6 in the first stage and 
0.7 overall, the target accrual was 15 patients in the first stage and an additional 22 patients 
in the second stage if ≥6 first-stage patients experienced a CR. Eligible patients had 
previously untreated AITL with measurable disease, performance status less than 3, and age 
>18 years. Baseline investigations included computed tomography scan of neck, chest, 
abdomen and pelvis, full blood count, biochemistry assessments, viral serology, 
autoimmune profile, direct antiglobulin test (DAT), bone marrow aspirate and bone marrow 
biopsy. 
Treatment consisted of fludarabine 40mg/m2 and cyclophosphamide 250mg/m2, 
administered orally on days 1-3 of each 28 day cycle. Restaging was performed after 4 
cycles. Patients progressing on FluCy came off trial. Patients in CR proceeded to thalidomide 
maintenance. 2 additional cycles of FluCy could be given to patients with stable disease (SD) 
or partial remission (PR) prior to thalidomide maintenance. Thalidomide was given as 
continuous therapy starting 4 weeks after the final cycle of FluCy. The initial dose was 
100mg daily increased every 4 weeks to a maximum dose of 300mg daily and could be 
continued for 6 months or until disease progression.  
Toxicity was graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events version 3.0. The protocol was approved by the South West 
Research Ethics Committee and the trial was conducted in accordance with the Declaration 
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of Helsinki. The primary endpoint was response rate following FluCy chemotherapy assessed 
according to standard criteria [13]. Secondary endpoints included response rate to 
thalidomide, progression-free (PFS), OS, and adverse events. The as-treated population, 
including all patients who received at least one dose of study treatment, was used for the 
analysis of all endpoints.  
Fifteen patients were recruited from 6 centers between February 2009 and March 2012. 
The median age was 68 years (range 52 – 91 years), and 13 patients (87%) had advanced 
stage disease with disease bulk (>10cm in any dimension) in 12 patients (80%). B symptoms 
were present in 11 (73%) patients. 12 patients (80%) were anaemic with haemoglobin 
<120g/l, a positive DAT was identified in 6/12 (50%) anaemic patients. Other autoantibodies 
identified were: anti-smooth muscle antibody (n=4), liver kidney microsomal antibody (n=2), 
and anti-mitochondrial antibody (n=1). Hypergammaglobulinaemia was present in 10/15 
(67%) patients which was polyclonal in 8/10 patients and due to a paraprotein in 2 patients. 
(Supplementary Table I) 
The histological diagnosis of AITL was confirmed by retrospective central review in 11/15 
cases (73%). There was insufficient histological material available for central review in one 
case. In the remaining 3 cases there was discrepancy between local and central histology 
review. PTCL was confirmed in 1 of these cases but not the specific diagnosis of AITL. In 2 
cases, central review indicated a diagnosis of T-cell rich DLBCL but the clinical features, 
aggressive disease course and, in one case, the findings on repeat biopsy at the time of 
relapse were considered by the treating center to be in keeping with a diagnosis of AITL.  
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Four or more cycles of FluCy were administered to 8 patients (53%). There were frequent 
dose reductions and delays due to toxicity. Treatment was delayed in 26% of cycles, the 
dose of fludarabine was reduced in 32% of cycles and cyclophosphamide dose reductions 
were made in 29% of cycles. Reasons for early cessation of treatment were hematological 
toxicity (n=2), death (n=2) and failure to respond (n=3). The 3 patients who terminated 
treatment early due to failure to respond were withdrawn from the trial in order to escalate 
therapy off protocol. Grade 3 or 4 hematological toxicity occurred in 8 (53%) patients, grade 
3 or 4 non-hematological toxicity was experienced in 9 (60%) patients. 
Responses were achieved in 9 patients (60%): CR n=5 (33%), CR unconfirmed n=1 (7%), 
Partial Response n=3 (20%). Progressive Disease occurred in four patients  (27%). Two 
patients only received 1 cycle of FluCy and response was not assessable in these patients. Of 
the 9 patients with at least stable disease after FluCy, 7 proceeded to thalidomide 
maintenance with a median dose of 150mg (range 100 – 600mg); thalidomide was 
continued for a median of 2 cycles (range 1-6). Two eligible patients did not continue to 
thalidomide maintenance due to hematological toxicity and disease progression before 
starting thalidomide respectively. Remission status did not improve in any patients receiving 
thalidomide maintenance and 4 patients progressed during (n=3) or within 3 months (n=1) 
of completing thalidomide.  One patient remains in remission 20 months after thalidomide. 
After a median follow-up of 22.6 months, 2 patients (13%) are alive without progression, 2 
patients (13%) are alive having progressed and 11 patients (73%) have died. Median PFS is 
5.5 months and median OS is 14.9 months. The causes of death in the 11 deceased patients 
were lymphoma (n=8), pneumonia (n=1), Crohn’s disease (n=1), and neutropenic sepsis 
(n=1).   
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The overall response rate to FluCy was 60%, with CR in 33%. The trial did not proceed to the 
2nd stage of recruitment as the CR rate was less than the pre-defined threshold of 40%. The 
CR rate was inferior to that reported with CHOP with or without rituximab [2, 6] and 
remissions were short lived with a median PFS of 5.5 months.  
Disruption of the interaction between the malignant cells and their microenvironment may 
explain some of the effect seen in patients with AITL treated with immunomodulatory drugs 
and we hypothesised that thalidomide may augment conventional chemotherapy through 
this mechanism [14, 15]. In this small trial, no patients experienced an improvement in 
remission status with thalidomide maintenance, however, the number of patients receiving 
sustained courses of thalidomide was too low to draw conclusions about its efficacy in this 
setting. 
One reason for the poor outcomes observed in this trial may have been frequent treatment 
delays and dose reductions consequent on the high toxicity rate in a predominantly elderly 
patient population. The trial design did not permit ASCT in first remission and recruiting 
centers may therefore have chosen not to enrol patients who were suitable for transplant 
and this may have skewed the population. The slow recruitment reflects the low incidence 
of AITL and highlights the difficulties in conducting prospective trials in this rare disease.  
The histological diagnosis of AITL can be difficult as demonstrated by the discrepancy 
between local and central pathology reports in 3 cases in this trial. When only the 11 
patients with centrally confirmed AITL are considered, the CR rate (36%) and ORR (64%) are 
not different from the trial population as a whole. In future trials, real-time prospective 
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central histology review should be used with additional patients recruited where there is 
diagnostic discrepancy.  
Due to the poor outcomes observed in this trial, we do not recommend FluCy as first-line 
treatment in AITL, and the current standard of care should be CHOP with or without 
rituximab, with enrolment into clinical trials assessing novel approaches wherever possible. 
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Variable N = 15 
   
 median (range) 
  
Age at registration, years 68 (52 – 91) 
  
 No. (%) 
Gender   
    Female 5 (33) 
    Male 10 (67) 
Performance status   
    0 2 (13) 
    1 9 (60) 
    2 4 (27) 
Clinical stage at study entry   
    II 2 (13) 
    III 4 (27) 
    IV 9 (60) 
B symptoms   
    Absent 4 (27) 
    Present 11 (73) 
Bulky disease   
    Absent 12 (80) 
    Present 3 (20) 
Bone marrow infiltration   
    Involved 6 (46) 
    Not involved 7 (54) 
    Missing 2  
Haemoglobin   
    <120g/l 12 (80) 
    ≥120g/l 3 (20) 
Platelets   
    <150x10
9
/l 3 (21) 
    ≥150x10
9
/l 11 (79) 
    Missing 1  
Paraprotein    
    Absent 8 (80) 
    Present 2 (20) 
    Missing 5  
Hypergammaglobulinaemia   
    No 5 (33) 
    Yes 10 (67) 
Direct antiglobulin test (DAT)   
    Negative 7 (54) 
    Positive 6 (46) 
    Missing 2  
Antimitochondrial antibody (AMA)   
    Negative 7 (88) 
    Positive 1 (13) 
    Missing 7  
Smooth muscle antibody (SMA)   
    Negative 4 (50) 
    Positive 4 (50) 
    Missing 7  
Liver/kidney/microsomal antibody (LKM)   
    Negative 7 (78) 
Angioimmunoblastic Lymphoma Trial 
 







Supplementary Table I Baseline characteristics of patients 
 
    Positive 2 (22) 
    Missing 6  
Serum Lactate Dehydrogenase (LDH)   
    <400IU/l 7 (47) 
    ≥400IU/l 8 (53) 
